Skip to content

Schrodinger SDGR Preferred Stock, Shares Outstanding

Preferred Stock, Shares Outstanding at other companies

Revvity logo
RevvityRVTY
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
Redwire logo
RedwireRDW
Charles River Laboratories logo
Charles River LaboratoriesCRL
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$58.6M-1.6%
Gross profit$29.5M-5.1%
Operating income-$48.8M+4.1%
Net income-$60.0M-0.4%
EPS (diluted)-$0.81+1.2%

Balance sheet

See full
Cash & equivalents$267.7M-20.7%
Total debt$107.0M-7.9%
Total equity$313.5M-16.1%
Total assets$634.2M-14.6%

Cash flow

See full
Operating cash flow-$14.8M-110%
CapEx$2.5M+321%
Free cash flow-$17.3M-112%

Valuation

See full
Market cap$1.15B-19.7%
Enterprise value$984.71M-18.3%
P/S4.5×-1.7×

Profitability

See full
Gross margin55.3%-7.3pp
Operating margin-64.7%-12.0pp
Net margin-68.5%
FCF margin9.6%+5.1pp

Returns & leverage

See full
Return on equity-45.7%
Debt / equity0.3×0.0×
Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's preferred stock, shares outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schrodinger's preferred stock, shares outstanding?
Schrodinger (SDGR) reported preferred stock, shares outstanding of $0 in Q1 2026.